Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells

Haematologica

Volumn 90, Issue 1, 2005, Pages 54-59

  Suárez, Lilia ^a,b   Vidriales, Marĩa Belén ^a,b   Moreno, María José ^c   López, Antonio ^d   García Laraña, José ^e   Pérez López, Cristina ^f   Tormo, Mar ^g   Lavilla, Esperanza ^h   López Berges, María Consuelo ^a   De Santiago, María ^d   San Miguel, Jesús F ^a,b   Orfao, Alberto ⁱ  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h HOSPITAL XERAL CALDE   (Spain)

ⁱ NONE

Author keywords

Acute myeloid leukemia; Apoptosis; Blast cells; Elderly and younger patients; Multidrug resistance

Indexed keywords

CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; GLYCOPROTEIN P; IDARUBICIN; LUNG RESISTANCE PROTEIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN; PROTEIN APO2.7; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; APOPTOSIS; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; ELDERLY CARE; FEMALE; HEMOLYSATE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PHENOTYPE; PROTEIN EXPRESSION;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; ANTIGENS, CD34; APOPTOSIS; BLAST CRISIS; DRUG RESISTANCE, MULTIPLE; FEMALE; GENES, MDR; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED;

EID: 19944431714     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Büchner T, Hiddemann W, Berdel W, Wormann B, Schock C, Loffler H, et al. Acute myeloid leukemia: treatment over 60. Rev Clin Exp Hematol 2002;6:46-59.
2. Pinto A, Zagonel V, Ferrara F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. The German AML Co-Operative Group. Crit Rev Oncol Hematol 2001;39:275-87.
3. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment or multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-9.
4. Venditti A, Del Poeta G, Buccisano F, Tamburini A, Cox-Frondllo MC, Bruno A, et al. Biological features of acute myeloid leukemia in the elderly. Blood 1998;92:697-9.
5. Stasi R, Del Poeta G, Venditti A, Masi M, Stipa E, Cox MC, Amadori S. Prognostic value of cytogenetics and multidrug resistance (MDR1) in elderly patients with acute myeloid leukemia. Blood 1998;92:695-7.
6. Del Poeta G, Venditti A, Stasi R, Aronica G, Cox MC, Buccisano F, et al. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. Leuk Res 1999;23:451-65.
7. Garrido SM, Cooper JJ, Appelbaum FR, Willman CL, Kopecky K, Banker DE. Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. Leuk Res 2001;25:23-32.
8. Willman CL. Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). Leukemia 1996;10 Suppl 1:533-5.
9. Tsimberidou AM, Paterakis G, Androutsos G, Anagnostopoulos N, Galanopoulos A, Kalmantis T, et al. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leuk Res 2002;26:143-54.
10. Borg AG, Burgess R, Green LM, Scheper RJ, Liu Yin JA. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells. Br J Haematol 2000;108:48-54.
11. Drenou B, Fardel O, Amiot L, Fauchet R. Detection of P glycoprotein activity on normal and leukemic CD34+ cells. Leuk Res 1993;17:1031-5.
12. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992;80:2729-34.
13. Suárez L, Vidriales B, García-Larana J, López A, Martínez R, Martín-Reina V, et al. Multi-parametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia. The PETHEMA Cooperative Group. Haematologica 2001;86:1287-95.
14. Wuchter C, Karawajew L, Ruppert V, Buchner T, Schoch C, Haferlach T, et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia 1999;13:1943-53.
15. + and CD34-blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica 2003;88:497-508.
16. Cascavilla N, Melillo L, D'Arena G, Greco MM, Carella AM, Sajeva MR, et al. Minimally differentiated acute myeloid leukemia (AML MO): clinico-biologicai findings of 29 cases. Leuk Lymphoma 2000;37:105-13.
17. Basso G, Lanza F, Orfao A, Moretti S, Castoldi G. Clinical and biological significance of CD34 expression in acute leukemia. J Biol Regul Homeost Agents 2001;15:68-78.
18. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56:3010-20.
19. List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 1996;10:937-42.
20. Legrand O, Simonin G, Zittoun R, Marie JP. Both P-gp and MRP contribute to drug resistance in AML. Leukemia 1998;12:1327-8.
21. Borg AG, Burgess R, Green LM, Scheper RJ, Liu Yin JA. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduce patient survival. Br J Haematol 1998;103: 1083-91.
22. Michieli M, Damiani D, Ermacora A, Masolini P, Raspadori D, Visani G, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br J Haematol 1999;104:328-35.
23. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81:3091-6.
24. Irvine AE, McMullin MF, Ong YL. Bcl-2 family members as prognostic indicators in AML. Hematology 2002;7:21-31.
25. Ong YL, McMullin MF, Bailie KE, Lappin TR, Jones FG, Irvine AE. High bax expression is a good prognostic indicator in acute myeloid leukaemia. Br J Haematol 2000;111:182-9.
26. Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003;101: 2125-31.
27. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposed revised criteria for the classification of the acute myeloid leukaemia. Ann Inter Med 1985;103:620-9.
28. Kappelmayer J, Gratama JW, Karaszi E, Menendez P, Ciudad J, Rivas R, et al. Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a. Interaction between monoclonal antibody clones, fluorochromes and sample preparation protocols. J Immunol Methods 2000;242:53-65.
29. Beck WT, Grogan TM. Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins. Leukemia 1997;11:1107-9.
30. Legrand O, Simonin G, Zittoun R, Marie JP. Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. Leukemia 1998;12:1367-74.
31. Marie JP, Legrand O, Perrot JY, Chevillard S, Huet S, Robert J. Measuring multidrug resistance expression in human malignancies: elaboration of Consensus recommendations. Semin Hematol 1997;4 Suppl 5:63-71.
32. Schroeijers AB, Reurs AW, Scheffer GL, Stam AG, de Jong MC, Rustemeyer T, et al. Up-regulation of drug resistance-related vaults during dendritic cell development. J Immunol 2002;168:1572-8.
33. Sunnaram BL, Gandemer V, Sebillot M, Grandgirard N, Amiot L, Leray E, et al. LRP overexpression in monocytic lineage. Leuk Res 2003;27:755-9.
34. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999;94:1086-99.
35. Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jager U, et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998;91:1508-13.
36. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996;87: 2464-9.
37. Borg AG, Burgess R, Green LM, Scheper RJ, Yin JA. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 1998; 103:1083-91.
38. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998;91: 4480-8.
39. Legrand O, Zittoun R, Marie JP. Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia 1999;13:578-84.